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Despite the tremendous progress made in the field of cancer therapy in recent years, certain 
solid tumors still cannot be successfully treated. Alongside classical treatments in the 
form of chemotherapy and/or radiotherapy, targeted treatments such as immunotherapy 
that cause fewer side effects emerge as new options in the clinics. However, these 
alternative treatments may not be useful for treating all types of cancers, especially for 
killing infiltrative and circulating tumor cells (CTCs). Recent advances pursue the trapping 
of these cancer cells within a confined area to facilitate their removal for therapeutic 
and diagnostic purposes. A good understanding of the mechanisms behind tumor cell 
migration may drive the design of traps that mimic natural tumor niches and guide the 
movement of the cancer cells. To bring this trapping idea into reality, strong efforts are 
being made to create structured materials that imitate myelinated fibers, blood vessels, 
or pre-metastatic niches and incorporate chemical cues such as chemoattractants or 
adhesive proteins. In this review, the different strategies used (or could be used) to trap 
tumor cells are described, and relevant examples of their performance are analyzed.
Keywords: tumor cell migration, tumor trap, biomimetic trap, cancer therapy, premetastatic niche recruitment
INTRODUCTION
For many decades, surgery, radiotherapy, and chemotherapy have served as the mainstay trident 
in the fight against cancer (Figure 1 Scheme I). During this period, the prognosis of many types of 
cancer has been significantly improved (Brustugun et al., 2018; Zeng et al., 2018; Iacobucci, 2019; 
Trama et al., 2019). However, the widespread use of these treatments has also uncovered several 
major limitations. For example, the feasibility of surgery is very much dependent on the localization 
and the size of the tumor. The procedure is also contraindicated in patients with poor clinical 
performance. As for radiotherapy and chemotherapy, these treatments are often implicated with 
serious side effects that, in some cases, may outweigh their potential therapeutic benefits. Moreover, 
these treatments lack the capacity to prevent metastases, which are responsible for roughly 90% of 
cancer-associated deaths (Rankin and Giaccia, 2016).
Numerous studies in the quest of improving cancer treatments are driven by the concept of 
“magic bullet’’ (Figure 1 Scheme II-2) put forward by the German scientist Paul Ehrlich (Strebhardt 
and Ullrich, 2008). If radio- and chemotherapy are considered as weapons of mass destruction, 
Ehrlich’s strategy can be regarded as the sniper of cancer therapy. This concept is mainly based 
on the idea of increasing the bioavailability and specificity of vector-associated active agents in 
the body while limiting their premature degradation and toxicity. In the context of anticancer 
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approaches, the success of selective therapies depends on the 
discovery of targeting elements that, when coupled with active 
ingredients and/or diagnostic cues, enable the recognition of 
well-characterized molecules, cells, or tissues. For example, 
Adcetris® targets the antigen CD30 in the treatment of Hodgkin’s 
lymphoma, and Kadcyla® targets HER2, which is present in about 
20% of breast cancer patients (Kim and Kim, 2015). Nevertheless, 
the discovery of appropriate targets that are specific to tumor cells 
remains a challenging task, despite the significant advancements 
made in the field of genomics and proteomics in recent decades. 
Fortunately, a plethora of new therapies are being approved 
regularly for the treatment of cancer. Among them is the use 
of locoregional therapies (Figure 1 Scheme II-1) that includes 
Nanotherm® (MagForce) that involves injection of magnetic 
nanoparticles inside the tumor or into the resection cavity. 
A magnetic field is then applied to generate heat via the 
nanoparticles and kill the cancerous cells locally (Maier-Hauff 
et al., 2011). It is currently licensed in Europe for the treatment 
of brain tumors and has received FDA approval in February 2018 
to be used in clinical trials involving prostate cancer patients 
(MagForce, 2018). Another example is Optune® (Novocure Ltd), 
a tumor-treating field (TTF) device composed of electrodes that 
can be placed on the patients’ scalp and connected to a generator 
to deliver a low-intensity electric field of 200 kHz (Taphoorn 
et al., 2018). It is believed to exert anticancer effects by disrupting 
the division of tumor cells (Giladi et al., 2015). The device has 
FIGURE 1 | Summary of the strategies that can be applied to fight cancers. (Scheme I) The classic treatments used for cancers are surgery, chemotherapy, and 
radiotherapy. (Scheme II) Innovative treatments include (1) locoregional therapy, (2) targeted therapy, and (3) tumor traps, among others. Tumor traps can be 
designed to take advantage of the migration pathways used by the tumor cells. It includes the use of tracks [(a) system developed by Jain et al. (2014) using aligned 
PCL fibers coated with laminin]. Tumor traps can be designed as synthetic pre-metastatic niches [(b) system developed by Seib et al. (2015) using a silk scaffold 
loaded with bone morphogenic protein 2 (BMP-2) capable of developing bone and marrow in vivo, (c) system developed by De Vlieghere et al. (2015) using iron 
oxide-coated microparticles encapsulating cancer-associative fibroblasts (CAFs) that continuously deposit ECM on the surface, (d) system developed by Azarin et al. 
(2015) using poly(lactide-co-glycolic acid) (PLGA) through the induction of the immune system by the CCL22 chemokine, and (e) system developed by De La Fuente 
et al. (2015) using a three-dimensional scaffold loaded with exosomes]. Finally, tumor traps can use chemoattractive molecules [(f) system developed by Giarra et al. 
(2018) using a methylcellulose (MC) thermo-responsive hydrogel loaded with stromal derived factor-1 (SDF-1) and (g) the system developed by Haji Mansor et al. 
(2018) using SDF-1 encapsulated in PLGA nanoparticles]. (4) Tumor traps can also be used for the early detection of metastasis [(a) system developed by Yoon 
et al. (2013) using graphene oxide nanosheets, (b) CELLSEARCH® CTC test (CELLSEARCH Circulating Tumor Cell, 2019) is a device using ferrofluid nanoparticles 
with EpCAM antibodies, and (c) system developed by Chen et al. (2016) using a nanoroughened glass substrate].
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been approved for the treatment of glioblastoma and shown to 
increase the median survival from 15 to 21 months when used 
on top of the standard treatments for this cancer (Stupp et al., 
2017). However, many countries and insurance companies do 
not cover the cost of this treatment, and the clinical adoption of 
this technology remains limited due to concerns regarding the 
lack of understanding of the device’s exact mechanism of action. 
Moreover, some skepticism exists toward the legitimacy of the 
device approval process due to the poor consideration of any 
placebo effect during the clinical trial phase (Fabian et al., 2019).
Among the numerous classes of novel anticancer treatments 
entering the market, cancer immunotherapy is arguably the one 
that is currently attracting the highest level of attention (Figure 1 
Scheme II-2). This class of treatment aims to treat cancer through 
artificial stimulation of the patient’s immune system (Zhang and 
Chen, 2018). The most cutting-edge subset of this type of treatment 
is the chimeric antigen receptor (CAR) T-cell immunotherapy, 
which involves harvesting T cells from a patient and genetically 
modifying these cells to express a receptor that can bind to a 
tumor antigen before injecting them back into the patient (Feins 
et al., 2019). CAR-T cell immunotherapy made its debut in the 
clinic in August 2017 when Kymriah® (Novartis) was approved 
by the FDA for the treatment of B-cell acute lymphoblastic 
leukemia (BCALL) (FDA, 2017a). This was followed by the 
approval of Yescarta® (Gilead Sciences) in October of the same 
year for the treatment of diffuse large B-cell lymphoma (FDA, 
2017b). Both Kymriah® and Yescarta® exert their effects by 
targeting CD19 antigen (Zheng et al., 2018). However, there are 
numerous ongoing clinical studies that explore the feasibility 
of targeting other antigens including PD-L1 (ClinicalTrials.
gov Identifier NCT03672305, NCT03198052, NCT03330834), 
EpCAM (ClinicalTrials.gov Identifier NCT03013712, 
NCT03563326, NCT02729493), and CD123 (ClinicalTrials.
gov Identifier NCT03796390, NCT02937103, NCT03672851). 
Many of these trials also attempt to evaluate the efficacy of 
CAR-T cell immunotherapy against solid tumors to expand its 
indication beyond certain blood cancers. More comprehensive 
reviews on the current status and future directions of CAR T-cell 
immunotherapy as well as other subsets of cancer immunotherapy 
such as immune checkpoint inhibitors and cancer vaccines 
can be found elsewhere (Dougan et al., 2018; Li et al., 2018; 
Sambi et al., 2019).
Despite the continuous increase in the number of novel 
anticancer treatments entering the clinic, local recurrence in 
previously healthy tissues seen in many cases of solid tumors 
remains an unsolved conundrum among clinicians and 
researchers alike. Development of new therapies for in situ control 
of the disease, while avoiding the problems of biological barriers 
and systemic toxicity, still proves to be a formidable task. Thus, 
in parallel to the innovative approaches mentioned previously, 
the idea of trapping infiltrative or circulating tumor cells (CTCs) 
within a confined area to facilitate their removal for therapeutic 
or diagnostic purposes has risen (Figure 1 Scheme II-3,4). Over 
the last years, this concept has developed progressively. The aim 
is twofold: a) to avoid the uncontrolled dissemination of tumor 
cells and b) to efficiently prevent the phenomenon of epithelial–
mesenchymal transition (EMT) or development of metastases. 
The concept is largely inspired by the “ecological trap” theory (van 
der Sanden et al., 2013). By considering cancers as ecosystems, it is 
possible to develop tumor traps not only for the infiltrative tumor 
cells, but also for the CTCs that are responsible for metastasis. 
However, imitating the traditional features of a natural habitat 
or niche for tumor cells and directing their migration pathways 
present numerous physical and biological challenges. The focus 
of this review will be on understanding the mechanisms of tumor 
cell migration and how this knowledge can be used to capture 
them, keeping in mind that different tumors are likely to utilize 
different mechanisms.
MIGRATION OF TUMOR CELLS
Tumor cells must cover a great distance on their journey to 
form metastases (Figure 2). The first step of the process is to 








(b) pores > 7 µm² (c) pores < 7 µm²
FIGURE 2 | Schematic representation of theorized paths of cancer cell migration away from the primary tumor. (1) Migration away from the primary tumor. Tumor 
cells can follow aligned tracks (a), or gradients of chemoattractant in solution (chemotaxis) or fixed on a substrate (haptotaxis) through the ECM. If the cross-
sectional area of the interfibrillar pore is more than 7 µm², degradation of the matrix is not needed (b); otherwise, a leader cell creates a path for the following cells 
thanks to MMPs (c). (2) Tumor cells adhere to a vessel and intravasate to reach the blood or lymphatic stream in which they circulate. (3) Once they reach a location 
where they can adhere to the vessel wall, the cells extravasate. (4) If the environment is favorable, a secondary tumor grows.
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migrate away from the primary tumor. Tumor cells can follow 
aligned tracks a), or gradients of chemoattractant in solution 
(chemotaxis) or fixed on a substrate (haptotaxis) through the 
extracellular matrix (ECM) b). If the cross-sectional area of 
interfibrillar pores is more than 7 µm², degradation of the matrix 
is not needed for cell movement. Alternatively, a leader cell 
can open a path for the following cells by virtue of the matrix 
metalloproteinase (MMP) activity c). The second step is to 
intravasate into the bloodstream or the lymphatic system in 
which the tumor cells will transit through the circulation. Third, 
cells extravasate to secondary tissues once they reach a location 
where they can adhere to the walls of the vessel. The fourth and 
final step deals with the formation of a secondary tumor. This 
only occurs if the environment is favorable to tumor growth. 
The different strategies implemented to mislead these cells 
into a trap are described in next sections. These strategies exploit 
the current knowledge on cancer cell migration and metastasis 
and the specificities of each type of tumor.
Migration Away From the Primary Tumor
The physical interactions between the ECM and cancer cells play 
a key role in allowing the cells to start migrating. Cancer cells 
may undergo an EMT to acquire a motile phenotype (Polyak 
and Weinberg, 2009). This translates into the loss of intracellular 
adhesion molecules such as E-cadherin and cytokeratins, 
resulting in detachment of the cells from the primary tumor, and 
an overexpression of MMP on their surface that allows the cells 
to digest laminin and collagen IV to progress in the dense ECM 
(Polyak and Weinberg, 2009). These changes are thought to be 
related to the stiffness of the matrix around the tumor, which is 
of higher values than that of normal tissues (Wozniak et al., 2003; 
Paszek et al., 2005; Kumar and Weaver, 2009; Levental et  al., 
2009). For example, the stiffness of GBM tissues is of ~25 kPa. 
while normal brain tissues have a stiffness of 0.1 to 1 kPa (Wang 
et al., 2014). Wang et al. investigated the effect of matrix stiffness 
on GBM cells and found that an increase in matrix rigidity could 
induce an upregulation of MMP-1, Hras, RhoA, and ROCK1 
(Wang et al., 2014), which are involved in increasing cell motility 
(Pulukuri and Rao, 2008; Liu et al., 2014; Wu et al., 2016; Li et al., 
2017). Another physical factor that governs the dissemination of 
cancer cells is the architecture of the extracellular environment, 
which includes pores of a diameter ranging from less than 1 to 
20 µm (Wolf et al., 2009). Matrix degradation is usually required 
for cancer cell migration to occur when the cross-sectional area 
of the interfibrillar pore is less than 7 µm², which corresponds 
to about 10% of the nuclear cross-section of cancer cells (Wolf 
et al., 2013). Above this value, cells can undergo deformation to 
migrate through the ECM.
Apart from the porosity of the ECM, the spatial arrangement of 
the matrix fibers near the primary tumor sites can also influence 
the motility of tumor cells; aligned fibers offer tracks that are more 
conducive to migration (Provenzano et al., 2008; Paul et al., 2017). 
These tracks are found along the ECM fibers in the interstitial 
space, between the muscle and nerve fibers, and along or within 
the vasculature of organs, among others (Gritsenko et al., 2012). 
Moreover, it has been observed that leader tumor cells are able to 
align collagen fibers to assist the migration of the following cells 
(Provenzano et al., 2006). In addition to creating the required 
physical space, these tracks also facilitate cancer cell migration by 
providing relevant molecular guidance. For example, cancer cells 
can be guided toward laminin and hyaluronan molecules in the 
ECM by their integrins and CD44 receptors, respectively, and also 
via haptotaxis by chemokines and growth factors immobilized 
along the tracks (Aznavoorian et al., 1990; Gritsenko et al., 2012). 
Jain et al. took inspirations from these biological phenomena and 
designed a scaffold to guide GBM cells toward a killing sink in 
an extracortical location (Figure 1 Scheme II-3-a) (Jain et al., 
2014). They utilized aligned poly-L-lysine and laminin-coated 
polycaprolactone (PCL) nanofibers (10 μm thick) encased in 
a PCL/polyurethane support (2.4 mm diameter) to imitate 
the white matter tracts (Bernstein and Woodard, 1995; Giese 
et al., 2003). The killing sink was composed of a collagen-based 
hydrogel conjugated to the chemotherapeutic agent cyclopamine. 
With this approach, the tumor mass of induced GBM in mice 
could be reduced. However, despite the positive results, this 
strategy as itself has limited clinical appeals, as the establishment 
of an extracortical sink in human patients may invite numerous 
technical difficulties. Instead, exploiting the local (intracortical) 
migration of the cancer cells may be a more translatable strategy 
to develop an efficient tumor trap for this cancer.
Intravasation and Tumor Cell Circulation
Tumor cells can circulate through the blood and lymphatic 
vessels on their journey to form a secondary tumor distant from 
the primary site (Chiang et al., 2016). This requires the cells to 
intravasate by passing through the endothelial cell junctions. 
Intravasation into the blood vessels occurs frequently due to 
the leaky nature of tumor vasculature. In addition, it has been 
observed in vivo that metastatic cells are able to polarize toward 
blood vessels. A possible explanation to this phenomenon 
is that these cells have an increased expression of epidermal 
growth factor (EGF) and/or colony-stimulating factor 1 (CSF-1) 
receptors. Thus, they migrate toward a gradient of EGF or CSF-1 
released by the macrophages lining the blood vessels (Wyckoff 
et  al., 2000; Wyckoff et al., 2004). However, it is still easier for 
tumor cells to enter the lymphatic system, as the surrounding 
ECM network is easier to penetrate and that the endothelial 
junctions are looser (Wong and Hynes, 2006). Either route can 
lead to blood vessel dissemination since the lymphatic circulation 
drains into the blood. As the lymphatic fluid is filtered by the 
lymph nodes, tumor cells are invariably invading them, starting 
with the nearest (Nathanson, 2003).
Once in the blood circulation, the trajectory of the tumor 
cells is influenced by the blood flow, the diameter of the blood 
vessels, and the intercellular adhesion (Wirtz et al., 2011). Two 
mechanisms can lead to the arrest of a CTC: physical occlusion 
and cell adhesion (Figure 3). Physical occlusion occurs when 
the diameter of the blood vessel is smaller or equal to the one 
of the CTC (usually around 10 µm). This has been observed in 
the brain by real-time imaging in a mouse model (Kienast et al., 
2010). Adhesion of CTCs to the vessel walls occurs when there 
is a balance between the adhesion force and the shear force 
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exerted inside the blood vessel (Zhu et al., 2008). When the shear 
force increases, the collisions between cells and the vessel wall 
increase, which in turn enhances the likelihood of cell adhesion. 
However, if the shear force is too high, turbulences may prevent 
the adhesion.
It is therefore possible to capture CTCs by designing a 
device with strong adhesive cues. Yoon et al. (2013) designed 
a microfluidic device consisting of graphene oxide nanosheets 
fixed onto a patterned gold surface to capture CTCs in early-
stage cancer for analytical purposes (Figure 1 Scheme II-4-a). 
The nanosheets were functionalized with epithelial cell adhesion 
molecule (EpCAM) antibody to capture CTCs. Blood samples 
were retrieved from healthy donors and mixed with labeled 
human breast cancer cell lines MCF-7 and Hs-578T and the 
human prostate cancer cell line PC-3. This microfluidic device 
captured more than 70% of the cancer cells in the prepared 
blood sample with high specificity. A similar principle was 
also implemented in the design of CELLSEARCH® CTC Test, 
the first and only clinically validated and FDA-approved blood 
test for enumerating CTCs (CELLSEARCH Circulating Tumor 
Cell, 2019). It allows for early assessment of patient prognosis 
as well as follow-up of the patient. The test constitutes the use 
of ferrofluid nanoparticles with EpCAM antibodies that bind to 
CTCs (Figure 1 Scheme II-4-b). Once magnetically separated 
from the rest of the blood sample, cells are stained to discriminate 
CTCs from leukocytes that can copresent in the sample. Working 
within the same domain of research, Chen et al. (2016) designed 
a nanoroughened glass substrate to capture CTCs based on 
their stronger adhesion capacity compared with normal blood 
cells (Figure 1 Scheme II-4-c). Such a working principle makes 
this device useful for capturing CTCs regardless of their surface 
marker expression profile, which is known to vary according to 
the type of cancer, patient demographics, and the state of the 
disease. It is indeed well discussed in the literature that the EMT 
process may lead to reduction in the epithelial cell adhesion 
molecule (EpCAM) expression in CTC (Hyun et al., 2016). The 
capture of CTC using EpCAM antibody alone may lead to an 
underestimation of the CTC number in the blood. With this 
device, more than 80% of cancer cells in whole blood samples 
from mice with induced breast cancer or lung cancer were 
captured independently of their EpCAM expression. Based on 
these findings, it is evident that a number of approaches can be 
adopted to capture CTCs to enable early detection of metastasis, 
although most of them are still far from translation to the clinic.
Extravasation and Secondary Tumor 
Formation
At the end of their time in blood circulation, the CTCs that 
survived and adhered to the blood vessel walls extravasate, and a 
fraction of these proceeds to form a secondary tumor. It has been 
shown experimentally that only about 0.01% of the cells in the 
circulation system eventually contribute to metastatic colonization 
(Fidler, 1970). The location at which they stop and grow into a 
secondary tumor is not believed to be randomly determined, and 
the reasons driving the selection of a particular site are still being 
investigated. In 1889, Paget et al. hypothesized that metastasizing 
cancer cells are like seeds that can only grow in the proper soil 
(Paget, 1889). Indeed, it has been observed that invasive cancer 
cells tend to migrate toward certain preferred sites of metastasis, 
a phenomenon that has been coined as “tissue tropism” (Seib 
et al., 2015). More recent studies revealed that the formation 
of certain microenvironments termed as pre-metastatic niches 
is crucial to the subsequent formation of metastatic tumors. 
These microenvironments consist of inflammatory immune 
cells, stromal cells, ECM proteins, tumor-secreted exosomes, and 
homing factors (Aguado et al., 2017). Tumor-secreted exosomes 
are sent to prime the niche at a target organ (often lungs, liver, 
brain, bone, and lymph nodes) by attracting bone marrow-
derived cells (BMDCs) as well as increasing the proliferation 
of fibroblast-like stromal cells (Peinado et al., 2012). BMDCs 
include CD11b+ myeloid cells, myeloid-derived suppressor cells, 
neutrophils, tumor-associated macrophages, and regulatory T 
cells. They are known to create an attractive site for metastasizing 
cells, and the presence of VEGFR1-positive BMDCs can serve 
as a predictor for the arrival of tumor cells (Kaplan et al., 
2005). Moreover, the establishment of a pre-metastatic niche is 
associated with an increased secretion of inflammatory cytokines 
and chemokines (Hiratsuka et al., 2006; Darash-Yahana et al., 
2009; Brennecke et al., 2014). The increasing understanding of 
Shear force > Adhesion force
Collision frequency high 
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FIGURE 3 | Mechanisms of arrest of a CTC: the influence of the shear force and the blood vessel diameter on the site of CTC extravasation.
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the pre-metastatic niches and their roles in welcoming metastatic 
dissemination has inspired scientists to create synthetic niches as 
a means to trap migrating cancer cells.
Creation of a Synthetic Pre-metastatic Niche to Trap 
CTCs
Many different strategies have been explored to engineer pre-
metastatic niches. For example, Seib et al. (2015) developed 
a tumor trap for the metastasizing cells of breast and prostate 
cancers by imitating the red bone marrow microenvironment 
(Figure 1 Scheme II-3-b). The strategy was adopted based on the 
knowledge that the bone was the preferred site of colonization in 
more than 60% of cases of metastasis for primary breast cancer 
and 73% for primary prostate cancer (Weiss, 1992). Evidence 
shows that red bone marrow attracts migrating cancer cells via 
chemotaxis with stromal derived factor-1 (SDF-1) (Taichman 
et al., 2002) and CXCL16 (Lee et al., 2013). It also provides 
adhesion sites that interact with tumor cell surface molecules 
such as annexin2 (Shiozawa et al., 2008), growth arrest-specific 
6 (GASP-6) (Shiozawa et al., 2010), CD44 (Hill et al., 2006), 
integrins (such as VLA-4, VLA-5, and LFA-1), and cadherins. 
Moreover, the bone marrow microenvironment is composed of 
osteoblasts, osteoclasts, stromal cells, stem cells, and mineralized 
bone marrow surrounded by a rich vascular bed, making it a 
perfect site for tumor growth (Mishra et al., 2011). To imitate the 
red bone marrow, Seib et al. designed a silk fibroin scaffold loaded 
with bone morphogenetic protein 2 (BMP-2) that is capable of 
developing bone and marrow in vivo. After implantation into 
the mammary fat pads of mice with induced breast or prostate 
tumor, no effect on the primary tumor growth was observed. 
However, metastatic growth could be seen taking place in the 
functionalized scaffolds, suggesting that it is possible to lure 
metastasizing cells into a trap by imitating the bone marrow 
microenvironment. A similar strategy was adopted by Bersani 
et al. (2014). They utilized a polyacrylamide hydrogel coated with 
bone marrow stromal cells (BMSCs), which was able to capture 
metastasizing cells of prostate cancer. 
De Vlieghere et al. (2015) took a slightly different approach to 
mimic a pre-metastatic niche by developing traps made of iron 
oxide-coated microparticles, encapsulating metabolically active 
cancer-associated fibroblasts (CAFs) (Figure 1 Scheme II-3-c). 
The CAFs continuously deposited ECM composed of type I 
collagen and tenascine C, among others, creating an adhesive 
environment for disseminated cancer cells. The microparticles 
were implanted into the peritoneal cavities of mice with induced 
ovarian cancer. Twenty-four hours after the implantation, the 
microparticles were magnetically removed, and the adhesion of 
cancer cells on the microparticles was assessed. The treatment 
led to a delay in peritoneal metastasis and prolonged the 
animal survival.
Another variation in the strategy for recruiting metastasizing 
cancer cells was presented by Azarin et al. (2015). They developed 
a microporous scaffold from poly(lactide-co-glycolic acid) 
(PLGA) scaffold for in vivo capture of metastasizing breast cancer 
cells through the induction of a local immune response (Figure 
1 Scheme II-3-d). Indeed, it has been shown that immune cells 
are implicated in tumor cell recruitment (Qian et al., 2009; Qian 
et al., 2011). Here, they have either recruited immune cells into 
the scaffold by grafting the chemokine CCL22, which is known 
to induce migration of immune cells but not tumor cells, or 
incorporated the Gr1hiCD11b+ immune cells directly into the 
PLGA scaffold. By doing this, they were able to reduce the 
number of breast cancer cells that metastasized to the lung by 
88%. Similarly, Rao et al. (2016) designed a poly(ε-caprolactone) 
(PCL)-based device with a slower degradation rate than PLGA 
scaffolds and investigated the immune response induced at the 
implantation site, the ability of the device to recruit metastatic 
cells for detection prior to colonization of organs as well as its 
influence on the survival of mice with induced breast cancer. 
Pelaez et al. (2018) further developed the strategy to enable 
the elimination of the attracted metastatic cells by noninvasive 
focal hyperthermia. To do so, they coupled metal discs to PCL 
microparticles to allow heat generation through electromagnetic 
induction using an oscillating magnetic field. The heat generation 
could be modulated conveniently by changing the size of the disc 
or the type of metal.
It has been shown that exosomes, which are vesicles involved 
in the transfer of information between cells, play a role in homing 
CTCs in the pre-metastatic niche (Peinado et al., 2012). De La 
Fuente et al. (2015) harnessed the potential of this knowledge 
and designed a three-dimensional scaffold with embedded 
exosomes extracted from the ascitic fluid of ovarian cancer 
patients (Figure 1 Scheme II-3-e). The scaffold, called M-Trap, 
was implanted in the inner wall of the peritoneum of mice with 
a xenograft of human ovarian cancer in the peritoneal cavity. 
They showed that the scaffold could serve as the preferred site 
of metastasis, while a peritoneal carcinometastasis was observed 
in the absence of the M-Trap. Moreover, an increase in the mean 
survival was observed in the presence of the M-Trap (from 117.5 
to 198.8 days), which was further improved by the removal of 
the scaffold (mean of survival of 309.4 days). The safety and 
performance of the M-Trap is currently being evaluated in a 
clinical trial involving female patients with stage IIIC ovarian 
cancer (ClinicalTrials.gov Identifier NCT03085238).
Chemoattraction of Tumor Cells
Migrating cells can make directional choices when presented 
with different migration pathways. In vitro, it has been shown that 
neutrophil-like cells can navigate through a microfabricated maze 
by following a chemical gradient (Skoge et al., 2016). Chemokines 
and their receptors are particularly involved in this navigation 
process. They are indeed responsible for the chemoattraction 
of various cells and could therefore be used to attract migrating 
tumor cells into a trap. Several receptors/chemokines have been 
identified to facilitate cancer cell migration. The most investigated 
one is SDF-1, also called CXCL12, which binds with high affinity 
to the CXCR4 and CXCR7 receptors. This chemokine is a 
pro-inflammatory mediator and is known to play a role in the 
recruitment of T cells, monocytes, and lympho-hemopoietic 
progenitor cells (Crump et al., 1997). Its overexpression has 
been linked to an increase in the invasiveness of ovarian cancer 
(Kajiyama et al., 2008), breast cancer (Bachelder et al., 2002; Zhan 
et al., 2016), and GBM (Barbero et al., 2003; Hira et al., 2017), 
among others [further details can be found elsewhere (Kryczek 
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et al., 2007)]. In addition, despite being less well studied, CXCL16 
and its receptor CXCR6 are also suspected to play a role in the 
migration of tumor cells. Wang et al. (2008) have shown that the 
expression of CXCR6 increases with the grade of prostate cancer. 
These results were supported by Lu et al. (2008) who observed 
that metastatic cells from prostate cancer overexpress the CXCR6 
receptor. Moreover, CXCL16 have been shown to induce the 
migration and enhance the proliferation of CXCR6-expressing 
cancer cells in vitro (Darash-Yahana et al., 2009).
With this knowledge, several groups have tried to stop the 
migration of tumor cells by inhibiting chemokine receptors, 
particularly the CXCR4 receptor. A reduction in the migration 
of cancer cells has been observed in vitro (Brennecke et al., 2014; 
Chittasupho et al., 2017; Zheng et al., 2017). However, this has 
not been successfully replicated in vivo. Brennecke et al. found 
that the use of CXCR4 antibody 12G5 can reduce the number of 
osteosarcoma pulmonary metastases having a diameter of <0.1 
mm but not those of larger dimensions (Brennecke et al., 2014). 
This finding can be explained by the fact that chemoattraction 
of cancer cells can be mediated by several pairs of chemokine–
receptor interaction (for example, SDF-1 can bind either CXCR4 
or CXCR7 or both, and CXCR6 can be activated by CXCL16). 
In addition, cells can activate the so-called compensation 
mechanisms in vivo to maintain their migration capacity. Indeed, 
it has been observed that neural progenitor cells (NPCs) are able 
to migrate in response to SDF-1 via the activation of the CXCR7 
receptor in response to the blockade of the CXCR4 receptor 
(Chen et al., 2015). Therefore, in order to stop the migration 
of tumor cells completely, all receptors implicated in in vivo 
chemoattraction should be identified and blocked, making the 
task nearly impossible. Moreover, this strategy could only work 
if the tumor cells have yet to begin migrating. In the particular 
case of GBM, cancer cells usually have already invaded the 
surrounding tissues at the time of diagnosis (Giese et al., 2003). 
Thus, it may be more useful to direct the migration of cells 
toward a desired location instead of blocking the migration 
process altogether.
Chemokines are already being used to attract cells into a 
scaffold for regenerative medicine purposes. The tumor trap 
concept can benefit from the existing knowledge in this field 
of application. Water-retaining polymer networks such as 
hydrogels and swellable matrices, which have been widely 
used in tissue engineering and regeneration, are pivotal 
platforms that are transferrable to the tumor trap application. 
For this purpose, biocompatible polymers capable of in situ 
formation of three-dimensional gels (Schesny et al., 2014; 
Shen et al., 2014; Addington et al., 2015) or matrices (Li et 
al., 2013; Yoon et al., 2013; Azarin et al., 2015; De Vlieghere 
et al., 2015; Ding et al., 2015; Autier et al., 2018) may be used 
to exert chemotaxis (based on a gradient of soluble attractant 
or repellant) or haptotaxis (based on a gradient of substrate-
bound extracellular matrix proteins) (Figure 4). Of particular 
interest is the potential exploitation of the CXCR4-SDF-1 
axis due to its prominent roles in regulating the migration of 
many types of cancer cells (Andreas et al., 2014; Schesny et al., 
2014; Addington et al., 2015; Goffart et al., 2015). Examples of 
biomaterials used to deliver SDF-1 for regenerative medicine 
are presented in Table 1. Recently, the development of SDF-1-
releasing scaffolds to attract tumor cells has received increasing 
attention. Giarra et al. (2018) designed a temperature-
responsive gel loaded with SDF-1 based on methylcellulose 
(MC) or poloxamers with or without hyaluronic acid (HA) 
for the purpose of attracting CXCR4-expressing GBM cells 
(Figure 1 Scheme II-3-f). Haji Mansor et al. (2018), on the 
other hand, encapsulated the chemokine in nanoparticles 
composed of PLGA and a (PEG)-PLGA copolymer to achieve 
sustained release (Figure 1 Scheme II-3-g). However, in both 
papers, no in vivo assessment on the ability of SDF-1 to attract 
migrating cancer cells was performed.
Challenges Associated With the Clinical 
Translation of the Tumor Trapping Strategy
While promising preclinical results have been obtained from the 
use of tumor traps as a diagnostic and/or therapeutic tool, there 
are multiple issues that must be addressed before this approach 
can enter the clinic. Main concerns include identifying suitable 
means for in vivo monitoring of the recruitment of cancer cells 
into the scaffolds to allow one to decide on the optimal time 
point for killing the trapped cancer cells. Prolonged duration of 
cancer cell recruitment may lead to overcrowding of the tumor 
trap and subsequent cell escape, reducing the purpose of the 
synthetic niche to merely a “relay” for the cancer cells en route to 










FIGURE 4 | Illustration of the use of scaffolds to attract motile tumor cells by chemotaxis (A) or haptotaxis (B).
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The incorporation of chemoattractant molecules such as 
SDF-1 into the tumor trap may also introduce additional 
complexities. In particular, there are concerns regarding the 
selectivity of SDF-1-mediated chemotaxis. Indeed, in addition 
to its role in recruiting cancer cells to local and distant sites of 
colonization, SDF-1 is also implicated in the homing of other 
cell lines such as immune cells and stem cells (Crump et al., 
1997; Wang et al., 2017; Hu et al., 2018). Moreover, the potential 
off-target effects may also be exacerbated by the fact that this 
chemokine is known to be involved in various processes that 
support tumor progression, angiogenesis, metastasis, and 
survival (Teicher and Fricker, 2010). It is therefore necessary to 
study in more detail the effect of injecting such proteins near 
tumor cells in vivo and to carefully evaluate the entire risks 
before moving to the clinic.
Further down the development timeline, the most effective 
way to kill the recruited cancer cells should be elucidated. It may 
be tempting to suggest direct removal of the trap to achieve an 
immediate eradication of the disease. However, this approach 
will necessitate an additional surgery, a requirement that may be 
very difficult to fulfill especially in patients who are terminally ill. 
A less invasive solution would be to use stereotactic radiotherapy 
(SRT). SRT is a treatment where radiation beam is directed to 
a well-defined spot, usually the tumor site, from many different 
angles around the body. The procedure ensures the targeted site 
receives much higher dose of radiation than the surrounding 
tissues. At the moment, SRT seems to be a viable option for killing 
the trapped cancer cells. This said, other selective approaches 
should also be considered and evaluated.
CONCLUSION
A good understanding of the escape pathways of a prey allows 
the hunter to capture it more efficiently; the same rule of thumb 
can be applied to tumor cells. Using this principle, it is possible 
to design tumor traps for diagnostic and/or therapeutic 
applications. For the latter purpose, it is necessary that the 
trapped cells are killed by the application of existing therapies. 
The different therapeutic strategies (surgery, chemotherapy, 
targeted therapy, …) may not be sufficient on their own to 
cure every cancer type, but they can be used in combination 
to achieve the best clinical outcomes. Jain et al. used a 
chemotherapeutic agent in the form of cyclopamine alongside 
their tumor trap to shrink down the size of GBM tumors (Jain 
et  al., 2014). It would also be interesting to combine the trap 
with radiosensitizers, focus x-ray, or γ-ray microbeams. Since 
the trap would concentrate the tumor cells, the efficiency of 
chemo- and radiotherapies can potentially be improved, while 
the associated side effects are likely to decrease. Immunotherapy, 
which can be broadly described as the activation of immune 
cells to make them able to recognize and eliminate tumor 
cells, could also be used. Indeed, one of the major difficulties 
in immunotherapy is to make the cancer cells accessible to the 
activated immune cells. This is particularly true in the brain, 
as there is a need to overcome the blood–brain barrier (Lyon 
et al., 2017). If immune cells can be preloaded or attracted into 
the trap via chemoattraction, this will facilitate the killing of the 
trapped cancer cells. Indeed, immune cells are also sensitive to 
a gradient of chemokines such as SDF-1 (Krieger et al., 2016) 
TABLE 1 | Strategies to load SDF-1 into different biomaterials.
Bonding strategy Type of biomaterial Composition Target site for regeneration Ref
Adsorption Hydrogel Hyaluronic acid Cardiac tissue (Purcell et al., 2012)
PPCN Wound healing (Zhu et al., 2016)
3D scaffold Collagen Cartilage (Chen et al., 2015)
Tendon (Sun et al., 2018)
Collagen/silk fibroin Bone (Hu et al., 2018)
Hydroxyapatite Bone (Zhang et al., 2018)
Decellularized skeletal  
muscle
Muscle (Rajabi et al., 2018)
Collagen/PLA Bone (Ritz et al., 2017)
PLGA Cartilage (Wang et al., 2017)





Hydrogel Heparin/PEG Cardiac tissue (Prokoph et al., 2012)
Blood vessel (Krieger et al., 2016)
Cardiac tissue (Baumann et al., 
2013)
3D scaffold Heparin/PLCL Blood vessel (Shafiq et al., 2017)
Heparin/PGS Blood vessel (Lee et al., 2013)
Heparin/PLLA Blood vessel (Yu et al., 2012)
Systems with nano/
microparticles
Microspheres Alginate Bone (Xu et al., 2018)
Hydrogel/ 
Nanoparticles
Hydrogel: CS/GP  
nano: CS/CMCS
Bone (Mi et al., 2017)
Microcapsules Dex-GMA/gelatin/ 
PNIPAAm
Wound healing (Chen et al., 2013)
Particles PLGA Cardiac tissue (Zamani et al., 2015)
PPCN, poly (polyethylene glycol citrate-co-N-isopropylacrylamide); PLA, polylactide; PLGA, poly(lactic-co-glycolic) acid; PCL, polycaprolactone; PEG, poly(ethylene-glycol); PLCL, 
poly(L-lactide-co-e-caprolactone) (PLCL); PGS, poly(glycerol sebacate); PLLA, poly(l-lactic acid); CS, chitosan; GP, beta-glycerol phosphate disodium salt; CMCS, carboxymethyl-
chitosan; Dex-GMA, glycidyl methacrylated dextran; PNIPAAm, poly(N-isopropylacrylamide).
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and can therefore be recruited into the trap together with the 
cancer cells of interest. Overall, this bio-integrative approach 
can be seen as counterintuitive insofar as the factors governing 
the trapping of tumor cells are also involved in other signaling 
pathways that may lead to effects that are opposite to the 
initial will (Komarova, 2015). Our current knowledge on the 
mechanisms driving the migration of cancerous cells might not 
be sufficient to develop a trap that only impacts tumor cells in a 
safe manner. The translation to the clinic will therefore require 
further investigations on the efficacy and safety of such systems. 
Nevertheless, as Albert Einstein pointed out, “we do not solve 
problems with the modes of thought that have engendered 
them,” and this unique approach therefore deserves further 
investigations.
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